Investors / filer profile

Orbimed Advisors LLC

active in 14 companies · 1 of 2 positions beat the S&P ~6mo later

Pro
Bought: Pro
Sold: 41
Filings: 14
Companies: 2026-08-10
Last filed

EDGAR · CIK 0001055951 ↗

Track record

How each disclosed position did against the S&P ~6 months later

The outcome curve and every position's resultPro →

+302.4%

median move per position

+6.3%

S&P 500 median, same spans

1 of 2

beat the S&P ~6mo later

4 positions still inside the ~6-month window — not scored yet.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$85.39M bought · −$66.96M sold

All filings on record

Every Form 4 transaction we track for this filer


BLSMBlossomHill Therapeutics, Inc.	Buy $10.00M · 625,000 sh	2026-08-10	—
BLSMBlossomHill Therapeutics, Inc.	Convert — · 1,049,283 sh	2026-08-10	—
BLSMBlossomHill Therapeutics, Inc.	Convert — · 1,039,996 sh	2026-08-10	—
BRVEBraveheart Bio, Inc.	Buy $4.92M · 273,333 sh	2026-08-07	—
BRVEBraveheart Bio, Inc.	Buy $30.00M · 1,666,667 sh	2026-08-07	—
BRVEBraveheart Bio, Inc.	Convert — · 9,132,420 sh	2026-08-07	—
SCTXScribe Therapeutics, Inc.	Buy $15.00M · 1,000,000 sh	2026-07-27	—
SCTXScribe Therapeutics, Inc.	Convert — · 348,825 sh	2026-07-27	—
ELVNEnliven Therapeutics, Inc.	Sell $2.10M · 46,776 sh	2026-06-22	—
ELVNEnliven Therapeutics, Inc.	Sell $35.72M · 787,024 sh	2026-06-22	—

BLSMBuy

2026-08-10 · BlossomHill Therapeutics, Inc.

$10.00M

—

BLSMConvert

2026-08-10 · BlossomHill Therapeutics, Inc.

1,049,283

—

BLSMConvert

2026-08-10 · BlossomHill Therapeutics, Inc.

1,039,996

—

BRVEBuy

2026-08-07 · Braveheart Bio, Inc.

$4.92M

—

BRVEBuy

2026-08-07 · Braveheart Bio, Inc.

$30.00M

—

BRVEConvert

2026-08-07 · Braveheart Bio, Inc.

9,132,420

—

SCTXBuy

2026-07-27 · Scribe Therapeutics, Inc.

$15.00M

—

SCTXConvert

2026-07-27 · Scribe Therapeutics, Inc.

348,825

—

ELVNSell

2026-06-22 · Enliven Therapeutics, Inc.

$2.10M

—

ELVNSell

2026-06-22 · Enliven Therapeutics, Inc.

$35.72M

—

Newest 10 of 41 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.